HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leiner Teetered Toward Bankruptcy As FDA Investigated Testing Fraud

This article was originally published in The Tan Sheet

Executive Summary

Whistleblowers' allegations of stability data manipulation at Leiner Health Products prompted the firm's rapid fall from a leading provider of private-label OTC drugs and dietary supplements to a property bought by a competitor in a bankruptcy court auction

You may also be interested in...



DOJ To Expand Use Of False Claims Act To Manufacturing And AER Violations

Drug manufacturers that sell to the government products that do not meet specifications or that fail to report serious adverse events could face False Claims Act allegations and potentially severe penalties in the near future

Leiner Files For Chapter 11 Protection, Explores Selling Business

Leiner Health Products' shutdown of its U.S. OTC operations a year ago forced the firm to seek Chapter 11 bankruptcy protection and explore selling its U.S. business

Leiner Asks FDA About Restarting U.S. OTC Operations, Posts $27.5 Mil. Loss

Heightened concerns over product quality triggered by adulterated Chinese imports and the need for more than one U.S. private-label supplier are fueling Leiner Health Products' optimism as it prepares to reenter the OTC market and recover from setbacks that led to a $27.5 million net loss in its latest quarter, CEO Robert Kaminski said Aug. 14

Related Content

Topics

UsernamePublicRestriction

Register

RS136873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel